153 related articles for article (PubMed ID: 9282174)
1. Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response.
Wendtner CM; Nolte A; Mangold E; Buhmann R; Maass G; Chiorini JA; Winnacker EL; Emmerich B; Kotin RM; Hallek M
Gene Ther; 1997 Jul; 4(7):726-35. PubMed ID: 9282174
[TBL] [Abstract][Full Text] [Related]
2. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection.
Janousková O; Síma P; Kunke D
Int J Oncol; 2003 Mar; 22(3):569-77. PubMed ID: 12579310
[TBL] [Abstract][Full Text] [Related]
3. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
Lu ZY; Condomines M; Tarte K; Nadal L; Delteil MC; Rossi JF; Ferrand C; Klein B
Exp Hematol; 2007 Mar; 35(3):443-53. PubMed ID: 17309825
[TBL] [Abstract][Full Text] [Related]
4. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
[TBL] [Abstract][Full Text] [Related]
5. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells.
Tarte K; Zhang XG; Legouffe E; Hertog C; Mehtali M; Rossi JF; Klein B
J Immunol; 1999 Jul; 163(1):514-24. PubMed ID: 10384156
[TBL] [Abstract][Full Text] [Related]
6. Oncoselective transduction of CD80 and CD86 in tumor cell lines using an autonomous recombinant parvovirus.
Gancberg D; Zeicher M; Bakkus M; Dupont F; Leo O; Moser M; Spegelaere P; Thielemans K; Urbain J; Horth M
Anticancer Res; 2000; 20(3A):1825-32. PubMed ID: 10928114
[TBL] [Abstract][Full Text] [Related]
7. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.
Wen XY; Mandelbaum S; Li ZH; Hitt M; Graham FL; Hawley TS; Hawley RG; Stewart AK
Cancer Gene Ther; 2001 May; 8(5):361-70. PubMed ID: 11477456
[TBL] [Abstract][Full Text] [Related]
8. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1.
Hirst WJ; Buggins A; Darling D; Gäken J; Farzaneh F; Mufti GJ
Gene Ther; 1997 Jul; 4(7):691-9. PubMed ID: 9282170
[TBL] [Abstract][Full Text] [Related]
9. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
10. Expression of costimulatory molecules CD80 and/or CD86 by a Kaposi's sarcoma tumor cell line induces differential T-cell activation and proliferation.
Foreman KE; Wrone-Smith T; Krueger AE; Nickoloff BJ
Clin Immunol; 1999 Jun; 91(3):345-53. PubMed ID: 10370381
[TBL] [Abstract][Full Text] [Related]
11. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE
J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593
[TBL] [Abstract][Full Text] [Related]
12. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
13. Immunogene therapy against mouse leukemia using B7 molecules.
Takahashi T; Hirano N; Takahashi T; Chiba S; Yazaki Y; Hirai H
Cancer Gene Ther; 2000 Jan; 7(1):144-50. PubMed ID: 10678367
[TBL] [Abstract][Full Text] [Related]
14. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production.
Schweitzer AN; Sharpe AH
J Immunol; 1998 Sep; 161(6):2762-71. PubMed ID: 9743334
[TBL] [Abstract][Full Text] [Related]
15. Transfer of activation-dependent gene expression into T cell lines by recombinant adeno-associated virus.
Zhang PX; Fuleihan RL
Gene Ther; 1999 Feb; 6(2):182-9. PubMed ID: 10435102
[TBL] [Abstract][Full Text] [Related]
16. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
17. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
18. B7.1 immunogene therapy effectively activates CD(4+) tumor-infiltrating lymphocytes in the central nervous system in comparison with B7.2 gene therapy.
Ando H; Saio M; Ohe N; Tamakawa N; Yu H; Nakayama T; Yoshimura S; Kaku Y; Iwama T; Shinoda J; Sakai N; Takami T
Int J Oncol; 2002 Apr; 20(4):807-12. PubMed ID: 11894129
[TBL] [Abstract][Full Text] [Related]
19. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells.
Liu Y; Chiriva-Internati M; You C; Luo R; You H; Prasad CK; Grizzi F; Cobos E; Klimberg VS; Kay H; Mehta JL; Hermonat PL
Cancer Gene Ther; 2005 Mar; 12(3):304-12. PubMed ID: 15565181
[TBL] [Abstract][Full Text] [Related]
20. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
